Literature DB >> 11892843

A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors.

B Zhang1, H Q Xia, G Cleghorn, G Gobe, M West, M Q Wei.   

Abstract

Lentiviral vectors pseudotyped with vesicular stomatitis virus glycoprotein (VSV-G) are emerging as the vectors of choice for in vitro and in vivo gene therapy studies. However, the current method for harvesting lentivectors relies upon ultracentrifugation at 50,000 g for 2 h. At this ultra-high speed, rotors currently in use generally have small volume capacity. Therefore, preparations of large volumes of high-titre vectors are time-consuming and laborious to perform. In the present study, viral vector supernatant harvests from vector-producing cells (VPCs) were pre-treated with various amounts of poly-L-lysine (PLL) and concentrated by low speed centrifugation. Optimal conditions were established when 0.005% of PLL (w/v) was added to vector supernatant harvests, followed by incubation for 30 min and centrifugation at 10,000 g for 2 h at 4 degrees C. Direct comparison with ultracentrifugation demonstrated that the new method consistently produced larger volumes (6 ml) of high-titre viral vector at 1 x 10(8) transduction unit (TU)/ml (from about 3,000 ml of supernatant) in one round of concentration. Electron microscopic analysis showed that PLL/viral vector formed complexes, which probably facilitated easy precipitation at low-speed concentration (10,000 g), a speed which does not usually precipitate viral particles efficiently. Transfection of several cell lines in vitro and transduction in vivo in the liver with the lentivector/PLL complexes demonstrated efficient gene transfer without any significant signs of toxicity. These results suggest that the new method provides a convenient means for harvesting large volumes of high-titre lentivectors, facilitate gene therapy experiments in large animal or human gene therapy trials, in which large amounts of lentiviral vectors are a prerequisite.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11892843     DOI: 10.1038/sj.gt.3301587

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  18 in total

1.  Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells.

Authors:  Lucas Chan; Darren Nesbeth; Taylor Mackey; Joanna Galea-Lauri; Joop Gäken; Francisco Martin; Mary Collins; Ghulam Mufti; Farzin Farzaneh; David Darling
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 2.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

3.  Production, purification and titration of a lentivirus-based vector for gene delivery purposes.

Authors:  Masoud Nasri; Ali Karimi; Mehdi Allahbakhshian Farsani
Journal:  Cytotechnology       Date:  2014-03-06       Impact factor: 2.058

4.  Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.

Authors:  Albert Grinshpun; Reba Condiotti; Simon N Waddington; Michael Peer; Eli Zeig; Sima Peretz; Alina Simerzin; Janice Chou; Chi-Jiunn Pann; Hilla Giladi; Eithan Galun
Journal:  Mol Ther       Date:  2010-06-22       Impact factor: 11.454

5.  Estradiol protects dermal hyaluronan/versican matrix during photoaging by release of epidermal growth factor from keratinocytes.

Authors:  Katharina Röck; Michael Meusch; Nikola Fuchs; Julia Tigges; Petra Zipper; Ellen Fritsche; Jean Krutmann; Bernhard Homey; Julia Reifenberger; Jens W Fischer
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

6.  Lentiviral-mediated RNA interference against TGF-beta receptor type II in renal epithelial and fibroblast cell populations in vitro demonstrates regulated renal fibrogenesis that is more efficient than a nonlentiviral vector.

Authors:  Tao Yang; Bing Zhang; Betty K Pat; Ming Q Wei; Glenda C Gobe
Journal:  J Biomed Biotechnol       Date:  2010-11-28

Review 7.  Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.

Authors:  Karine Breckpot; David Escors
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2009-12       Impact factor: 2.895

8.  A new chemical complex can rapidly concentrate lentivirus and significantly enhance gene transduction.

Authors:  Jing-Yu Lee; Hu-Hui Lee
Journal:  Cytotechnology       Date:  2017-09-07       Impact factor: 2.058

9.  Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes.

Authors:  Fulya Erendor; Yunus Emre Eksi; Elif Ozgecan Sahin; Mustafa Kemal Balci; Thomas S Griffith; Salih Sanlioglu
Journal:  Mol Ther       Date:  2020-10-31       Impact factor: 11.454

10.  Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis.

Authors:  Sören Twarock; Till Freudenberger; Eva Poscher; Guang Dai; Katharina Jannasch; Christian Dullin; Frauke Alves; Klaus Prenzel; Wolfram T Knoefel; Nikolas H Stoecklein; Rashmin C Savani; Bernhard Homey; Jens W Fischer
Journal:  Mol Cancer       Date:  2011-03-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.